[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346566-105":59,"doc-detail-346566-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-role-of-cd26-in-breast-cancer-and-its-pan-cancer-analysis","The role of CD26 in breast cancer and its pan-cancer analysis","","CD26 (DPP4) is implicated in multiple tumors and antitumor immunity, but its pan-cancer and context-dependent roles remain insufficiently defined. This study characterizes CD26’s clinical relevance and links it to invasion-associated features, immunotherapy-relevant immune infiltration, and biomarkers tied to treatment response, with experimental validation in breast cancer cells. Pan-cancer bioinformatics integrates expression, enrichment, immune correlations, and staging/prognostic evaluation, followed by in vitro assays in MCF-7 and MCF-10A cells.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-role-of-cd26-in-breast-cancer-and-its-pan-cancer-analysis/346566/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-role-of-cd26-in-breast-cancer-and-its-pan-cancer-analysis/346566.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main objective of the study on CD26?","Question",{"text":112,"@type":113},"To comprehensively characterize the clinical relevance of CD26 across cancers, link its expression to invasion-related features and immunotherapy-relevant immune markers, and validate key findings in breast cancer cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the pan-cancer analysis of CD26 performed?",{"text":117,"@type":113},"Using public databases to evaluate expression patterns, associations with cancer stage and prognosis, and to infer pathways through GO/KEGG enrichment with co-expression and protein-interaction data.",{"name":119,"@type":110,"acceptedAnswer":120},"What experimental evidence was tested in breast cancer cells?",{"text":121,"@type":113},"CD26 expression was compared between MCF-7 and MCF-10A cells, and pharmacologic CD26 inhibition with alogliptin was used to assess effects on proliferation, invasion, and MMP9 expression in vitro.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},346566,1790158751,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Tao et al. BMC Cancer (2026) 26:317 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-15656-5](https://doi.org/10.1186/s12885-026-15656-5)  \nRESEARCH Open Access  \nThe role of CD26 in breast cancer and its pan- cancer analysis  \nRunyi Tao1,2†, Bohao Liu1,2†, Shan Gao1,2, Jingyi Zhang1,2, Jizhao Wang1,2, Qiuyu Gong1,2, Xingzhuo Zhu1,2, Yilong Zhao1,2, Jiaqi Huang1,2, Chenrong Zhang1,2, Yixing Li1,2, Zhiyu Wang1,2 and Guangjian Zhang1,2*  \nAbstract  \nBackground CD26 (DPP4) is shown in literature to be implicated in multiple tumors and antitumor immunity, yet itspan-cancer and context-dependent roles remain imprecisely defined. This study comprehensively characterizes the clinical relevance of CD26 and its association with invasion-related features and immunotherapy-relevant immune infiltration and response-associated biomarkers, and to validate key findings in breast cancer cells.  \nMethods The integrated pan-cancer analysis of CD26 was performed using public databases, assessing its expression patterns, associations with cancer staging and prognostic value. Co-expression and protein-interaction data were used for GO/KEGG enrichment to infer potential biological pathways. Correlations between CD26 and immune cell infiltration, cancer-associated fibroblasts (CAFs), immune checkpoints, tumor mutational burden (TMB), microsatellite instability (MSI), and neoantigen load were systematically evaluated. R software and online bioinformatics tools were employed. Additionally, qPCR, western blot and other in-vitro experiments compared CD26 expression in MCF-7 breast cancer cells and MCF-10A normal breast epithelial cells, and examined the effects of pharmacologic CD26 inhibition (alogliptin) on proliferation, invasion, and MMP9 expression in vitro.  \nResults CD26 exhibited broad but low tissue specificity and was significantly upregulated in multiple malignancies compared with normal tissues, particularly in highly aggressive tumors (P \u003C 0. 01) . Higher CD26 expression was associated with advanced pathological stage and adverse prognosis in several tumor types (p \u003C 0. 01), including breast cancer, while exhibiting a favorable prognostic association in a subset of tumors, indicating context-dependent relationships. Functional enrichment suggested involvement of CD26-related networks in chemokine signaling and EMT-related processes. CD26 expression correlated with estimated immune infiltration in 34 of 38 tumor types, including CD4+ and CD8+ T cells and CAFs, and was associated with multiple immune checkpoints, as well as TMB, MSI and neoantigens in selected cancers. In vitro, CD26 was elevated in MCF-7 versus MCF-10A cells (p \u003C 0. 05), andalogliptin treatment reduced MCF-7 cell proliferation and invasion (p \u003C 0. 05), accompanied by decreased MMP9 expression (p \u003C 0. 05) .  \nConclusions This study presents an integrative pan-cancer framework linking CD26 expression to immune infiltration, together with in vitro observations in breast cancer cells, offering a comprehensive pan-cancer and  \n†Runyi Tao and Bohao Liu have contributed equally to this study.  \n*Correspondence: Guangjian Zhang [michael8039@xjtu.edu.cn](michael8039@xjtu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not incl","cbCaikBUHsvOw35Y","https://ap.wps.com/l/cbCaikBUHsvOw35Y","pdf",6380774,18,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Immune checkpoint therapy context\n## CD26 biology and immune relevance","[{\"question\":\"What is the main objective of the study on CD26?\",\"answer\":\"To comprehensively characterize the clinical relevance of CD26 across cancers, link its expression to invasion-related features and immunotherapy-relevant immune markers, and validate key findings in breast cancer cells.\"},{\"question\":\"How was the pan-cancer analysis of CD26 performed?\",\"answer\":\"Using public databases to evaluate expression patterns, associations with cancer stage and prognosis, and to infer pathways through GO/KEGG enrichment with co-expression and protein-interaction data.\"},{\"question\":\"What experimental evidence was tested in breast cancer cells?\",\"answer\":\"CD26 expression was compared between MCF-7 and MCF-10A cells, and pharmacologic CD26 inhibition with alogliptin was used to assess effects on proliferation, invasion, and MMP9 expression in vitro.\"}]","The role of CD26 in breast cancer and its pan-cancer analysis | PDF",1790061994,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5fbfcdea31757dce774eb4e27455232c.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8b49d16f89b8083c9fdce113d0bc5081.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/08cd1052476d189327fa48eeacc6d323.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d54187cf9167f674cafe22ef38e5907.webp",980,1306]